A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics.Chaikuad, A., M C Tacconi, E., Zimmer, J., Liang, Y., Gray, N.S., Tarsounas, M., Knapp, S.
(2014) Nat Chem Biol 10: 853-860
- PubMed: 25195011
- DOI: 10.1038/nchembio.1629
- Structures With Same Primary Citation
- PubMed Abstract:
Activation of the ERK pathway is a hallmark of cancer, and targeting of upstream signaling partners led to the development of approved drugs. Recently, SCH772984 has been shown to be a selective and potent ERK1/2 inhibitor. Here we report the structu ...
Activation of the ERK pathway is a hallmark of cancer, and targeting of upstream signaling partners led to the development of approved drugs. Recently, SCH772984 has been shown to be a selective and potent ERK1/2 inhibitor. Here we report the structural mechanism for its remarkable selectivity. In ERK1/2, SCH772984 induces a so-far-unknown binding pocket that accommodates the piperazine-phenyl-pyrimidine decoration. This new binding pocket was created by an inactive conformation of the phosphate-binding loop and an outward tilt of helix αC. In contrast, structure determination of SCH772984 with the off-target haspin and JNK1 revealed two canonical but distinct type I binding modes. Notably, the new binding mode with ERK1/2 was associated with slow binding kinetics in vitro as well as in cell-based assay systems. The described binding mode of SCH772984 with ERK1/2 enables the design of a new type of specific kinase inhibitors with prolonged on-target activity.
1] Structural Genomics Consortium, University of Oxford, Old Road Campus Research Building, Oxford, UK.  Department of Biochemistry and Molecular Medicine, George Washington University, Washington, DC, USA.  Target Discovery Institute, University of Oxford, Nuffield Department of Medicine Research Building, Oxford, UK.